PET imaging

Telix Pharmaceuticals' glioma imaging candidate TLX101-Px gains European regulatory validation, entering 210-day review phase with potential market approval expected.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.

FDA accepts Telix's Pixclara NDA for glioma imaging with September 2026 decision target. Orphan Drug designation provides competitive advantages.

Radiopharm Theranostics and Siemens Healthineers sign manufacturing supply agreement for RAD101 PET imaging agent, advancing toward Phase 3 trial with strong interim data.

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.